CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Antibiotics +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03644966
NCT03644966N/ACompleted
CompareCT.gov

Probiotic and Effects on Multi-Drug Resistant Urinary Tract Infection

Ochsner Health System·interventional·Posted Aug 23, 2018·Updated Apr 12, 2023

In Brief

A clinical study evaluating Bifidobacterium infantis, Placebo, and 1 other intervention for Urinary Tract Infections and 2 related conditions. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This pilot study is a single-site randomized, double blinded placebo-controlled in females with recurrent multi-drug resistant (MDR) urinary tract infections(UTI). Our study hypothesizes that a novel probiotic strain improves antibiotic sensitivity patterns in these former MDR UTIs.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Tract Infections, Recurrent UTI, Antibiotic Resistant Infection
CountriesUnited States
CollaboratorsProcter and Gamble

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 23, 2018
Enrollment StartJul 5, 2018
Primary CompletionDec 15, 2022
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 7.9 years ago

Interventions

Bifidobacterium infantisdietary

Probiotics

Placeboother

Sugar pill manufactured to mimic probiotic tablet

Antibioticsdrug

Per Infectious Disease Society guidelines for Antimicrobial treatment of uncomplicated cystitis and pyelonephritis in women